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Abstract: A gel-based proteomics approach was used to screen for proteins of differential 
abundance between the saliva of smokers and those who had never smoked. Subjecting 
precipitated proteins from whole human saliva of healthy non-smokers to two-dimensional 
electrophoresis (2-DE) generated typical profiles comprising more than 50 proteins. While 
35 of the proteins were previously established by other researchers, an additional 
22 proteins were detected in the 2-DE saliva protein profiles generated in the present study. 
When the 2-DE profiles were compared to those obtained from subjects considered to be 
heavy cigarette smokers, three saliva proteins, including interleukin-1 receptor antagonist, 
thioredoxin and lipocalin-1, showed significant enhanced expression. The distribution 
patterns of lipocalin-1 isoforms were also different between cigarette smokers and   
non-smokers. The three saliva proteins have good potential to be used as biomarkers for 
the adverse effects of smoking and the risk for inflammatory and chronic diseases that are 
associated with it. 
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1. Introduction 
Cigarette smoking is the most preventable cause of addiction, sickness and mortality in the world. 
Death attributed to cigarette smoking is estimated to rise from 5.4 million in 2005 to 6.4 million by 
2015 [1]. Chronic cigarette smoking is the single most important risk factor for lung and oral cancers, 
cardiovascular diseases, chronic obstructive pulmonary disease (COPD) and other tobacco related oral 
diseases, including periodontitis [2–7]. Cigarette smoke contains more than 60 carcinogens and around 
4,000 chemicals, including bacteria-derived endotoxins, which are toxic to cells [8–10]. The risk of 
developing tobacco smoking-related diseases increases with the total exposure time to the cigarette 
smoke, which generally includes the number of cigarettes a person smokes each day and the number of 
years a person has been smoking [11]. 
The oral cavity is the first organ in the human body to be exposed to the cigarette smoke. The 
tobacco smoke alters normal homeostasis of the oral cavity, including the saliva’s antioxidant and 
other protective systems. This may lead to oral inflammatory diseases and oral cancers [12–15]. Early 
tumorigenic activities have been detected in normal oral mucosa of heavy smokers who have no overt 
precancerous or cancerous lesions [16]. The mucosal changes in smokers may also arise from the 
drying effects of the mucosa, high intraoral temperatures, intraoral pH changes, local alteration of 
membrane barriers and immune responses, or altered resistance to bacteria, fungal and viral infections. 
Smoking-related cell damage may leave molecular footprints in the saliva, offering the potential for 
non-invasive early diagnosis of tobacco-related oral diseases.  
Human saliva contains a large number of proteins and peptides that are easily accessible and may 
serve as a potential source of biomarkers to monitor changes that occur under pathological conditions. 
The value of saliva as a biological fluid for the detection of diagnostic and prognostic biomarkers has 
become increasingly well established [17–24]. Collection of human saliva is a simple, non-invasive 
and cost-effective approach for screening large populations. It is easy to handle and may be repeated 
without inflicting much discomfort to the subjects [17,18].  
Proteomic analysis is an important investigative tool used to systematically explore cellular proteins 
that are responsive to adverse environmental challenges. Several proteomic approaches, including 
those involving separation of proteins by two-dimensional electrophoresis (2-DE), have been applied 
in the investigation of biomarker candidates in the human saliva [25–29]. Recently, saliva has been 
shown to harbor potential informative biomarkers for oral cancer [30–32], head and neck   
cancer [33,34], and breast cancer [35]. While effects of the cigarette smoke on proteins expressed in 
the bronchoalveolar lavage [36–38], nasal lavage fluid [39], urine [40], lung tissue [41], bronchial 
airway epithelium and pooled exhaled breath condensate samples [42] have been analyzed, little 
information is available regarding the effects of smoking on the whole saliva proteome.  
To the best of our knowledge, there had been no reported studies that specifically compared the 
expression of proteins in the saliva of smokers and non-smokers. In this study, 2-DE-based proteomics 
was used to screen for saliva proteins of differential abundance between smokers and subjects who had 
never smoked. The aberrantly expressed proteins, when correlated to those similarly altered in the Int. J. Mol. Sci. 2010, 11          
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saliva of patients with tobacco-related diseases including oral cancer, may potentially be used as 
biomarkers to indicate risks for the various diseases. 
2. Materials and Methods 
2.1. Collection of Whole Saliva 
Unstimulated whole saliva samples were collected from 24 healthy Malay male volunteers aged 
between 35 and 55 years (12 smokers and 12 non-smokers), with no history of diabetes, autoimmune 
diseases or exposure to radiation and chemotherapy. Characteristics of the participants who were 
considered heavy smokers in this study are shown in Table 1. Saliva samples were collected with the 
volunteers’ consent and approval granted by the Ethical committee (Institutional Review Board) of the 
Faculty of Dentistry, University of Malaya. Each subject answered a questionnaire concerning 
personal data, smoking and alcohol drinking habits, health or dental problems, oral hygiene habits, 
previous dental examinations, use of prescriptions, quantity and length of cigarette smoking. 
Unstimulated whole saliva was collected in the morning between 9 and 11  am to minimize the 
circadian effect, and subjects refrained from eating, drinking, smoking or performing any oral hygiene 
for at least 2 h prior to the collection. The difference between the mean flow rates of non-smokers 
(0.39 ± 0.04 mL/min) and smokers (0.42 ± 0.04 mL/min) was not statistically significant. Protease 
inhibitor cocktail was added to the saliva immediately after collection as previously described [43]. To 
remove debris and cells, the saliva was centrifuged at 14,000 g for 20 min at 4 °C and the proteins 
were precipitated in 10% TCA/acetone/20 mM DTT. Saliva proteins were quantified using the 
Bradford protein assay kit (Bio-Rad, Hercules, USA) according to the manufacturer’s instructions. 
Table 1. Demographics and smoking history of smoker subjects. 
Subject
(a)  Age  Cigarettes/Day  Smoking Duration
(b)  Stick-year
(c) 
1 35  20  15  300 
2 36  14  23  322 
3 38  20  15  300 
4 51  14  20  280 
5 36  14  15  210 
6 54  20  30  600 
7 38  20  17  340 
8 54  30  30  900 
9 39  20  20  400 
10 39  20  25  500 
11 48  24  17  408 
12 40  14  15  210 
(a) All subjects were male and of Malay ethnicity; 
(b) Duration
 in years since first started smoking;  
(c) Stick-year of exposure is in accordance to the Brickman index, which is the number of cigarettes 
smoked per day multiplied by the smoking duration. 
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2.2. Two-Dimensional Electrophoresis 
Two-dimensional electrophoresis (2-DE) was performed as previously described [43]. Saliva 
proteins (130 µg) were dissolved in rehydration buffer containing 7 M urea, 2 M thiourea, 4% CHAPS, 
0.5% IPG buffer, 65 mM DTT and 0.002% bromophenol blue and applied onto 13 cm rehydrated 
precast immobilized drystrips pH 4–7 (GE Healthcare BioSciences, Uppsala, Sweden). Isoelectric 
focusing (IEF) for the first dimension and SDS-PAGE for the second dimension were performed as 
described previously [43]. All samples were analyzed in triplicate. 
2.3. Silver Staining 
The 2-DE gels were developed by silver staining as described by Heukeshoven and Dernick [44]. 
For mass spectrometry analyses, gels were stained with compatible silver staining with slight 
modifications according to Yan et al. [45]. 
2.4. Image Analysis 
The LabScan image scanner was used to capture and store images of 2-DE gels. The GE 
ImageMaster
TM 2D Platinum Software version 7 was used to evaluate the protein profiles and perform 
protein analyses. To detect proteins that were differentially secreted in the saliva, the percentage 
volume contribution (% vol) of a protein spot, which refers to the spot volume of a protein expressed 
as a percentage of the total spot volume of all detected saliva proteins, was calculated. Data expressed 
this way are independent of variations attributed to protein loading and staining. The 2-DE profiles and 
relative spot intensities obtained were reproducible when performed in triplicate.  
2.5. In Gel Trypsin Digestion and Mass Spectrometry  
Highly resolved protein spots were initially identified by visual comparison with previously 
published protein maps obtained from the human whole saliva [22–26]. The protein spots (1–2 mm 
diameter) were excised from silver-stained gels with pipette tips and kept hydrated in clean microfuge 
tubes containing Milli-Q water, prior to the in-gel digestion. Trypsin digestion and precise 
identification by mass spectrometry, using the MALDI-TOF/TOF instrument (Applied Biosystem 
4800 Proteomic Analyzer), were performed as previously described [46]. 
2.6. Database Searches 
Spectra were processed and analyzed by the Global Protein Server Workstation (Applied 
Biosystems), which uses the internal MASCOT (Matrix Science, London, UK) software for search of 
the peptide mass fingerprints and MS/MS data. Searches were performed against the Swiss-Prot 
database (Last update: October 23, 2008, containing 261513 sequences). Database search parameters 
were set as follows: The enzyme trypsin was used; up to one missed cleavage was allowed; variable 
modification included were carbamidomethylation of cysteine and oxidation of methionine; the mass 
tolerance for MS precursor ion and MS/MS fragment ion were 100 ppm and 0.2 Da, respectively; and 
only monoisotopic masses were included in the search. 
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2.7. Statistical Analysis 
All values are presented as mean ± S.E.M (standard error of the mean). The Student’s t-test was 
used to analyze the significance of difference between non-smokers and smokers. The false discovery 
rate control was performed using the method of Benjamini and Hochberg [47].  
3. Results 
Figure 1 shows a typical 2-DE profile of saliva proteins separated between pH 4 and 7 in healthy 
non-smokers. This range of pH was chosen as our earlier 2-DE results performed at a pH range of 3 to 
10 showed that most of the saliva proteins were located in the acidic region between pH 4 to 7. More 
than 120 spots were detected in the whole saliva samples using the 2-DE that was performed under the 
conditions of our study. Identities of 108 spots belonging to 57 different proteins were established by 
MS and database search (Table 2). Some of these proteins, including polymeric immunoglobulin 
receptor (spots  3–9), carbonic anhydrase VI (spots  27–32), prolactin inducible proteins   
(spots 81–86), zinc-alpha-2-glycoprotein (spots 43 and 44), short palate, lung and nasal epithelium  
carcinoma-associated protein 1 (spots  58–61), cystatin S (spots  90 and 91) and lipocalin-1   
(spots 87–89) were resolved in several isoforms and thus separated into distinct spots in the 2-DE gels. 
Figure 1. Typical 2-DE profile of precipitated saliva proteins obtained from non-smokers. 
A total of 108 protein spots (circled and numbered) were identified by mass spectrometry 
and database search (please refer to Table 2). Acid side of 2-DE gel is to the left and 
relative molecular mass declines from the top. 
 Int. J. Mol. Sci. 2010, 11          
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Table 2. Identification of saliva proteins by mass spectrometry. 
Accession 
No. 
(a) 
Protein Spot 
No.
(b) 
MASCOT 
Score 
No. of Peptides 
Hit 
Sequence 
Coverage 
Ref. 
P02787  Serotransferrin  1  89  10  9  [22,23,25] 
2  78  16  8 
[22–26]  P01833 
 
Polymeric immunoglobulin 
receptor  
3 282  9  8 
4 111  11  33 
5 99  17  27 
6 240  7  22 
7 246  20  55 
8 169  12  32 
9 120  18  28 
Q9Y6R7  IgGFc-binding protein  10  645  10  2  Npd 
Q8TDL5  *Long palate, lung and nasal 
epithelium carcinoma-
associated protein 1 
11 187  4  11  Npd 
P09960  *Leukotriene A-4 hydrolase  12  376  6  14  Npd 
P02768  Serum albumin   13  98  3  5  [22–26] 
14 122  5  7 
P04745  Human salivay α-amylase
   15  101  15  27  [22–26] 
P08107 
 
Heat shock 70 kDa protein 1  16  572  8  14  [23] 
P13796  Plastin-2   17  555  32  16  Npd 
P07237 *Protein  disulfide-isomerase    18  636  13  27  Npd 
P02774 
 
Vitamin D-binding protein 
precursor 
19  741  11  32  [27] 
20  575  10  27 
P01009 
 
Alpha-1-antitrypsin
  
  
21 211  8  10  [25] 
22 112  6  12 
23 99  5  18 
P61158  Actin-related protein 3  24  327  13  17  Npd 
P50395 *Rab  GDP  dissociation 
inhibitor beta 
25 363  15  19  [28] 
P06733  Alpha-enolase  26  735  11  33  [22,23,26] 
P23280 
 
Carbonic anhydrase VI 
 
27 290  15  19  [22,23] 
28 90  4  4 
29 303  11  40 
30 488  32  48 
31 79  4  8 
32      
P30740  *Leukocyte elastase inhibitor  33  374  12  19  [29] 
  34  315  10  16 
Q99536  **Synaptic vesicle  membrane 
protein VAT-1 
35 76  2  4  Npd 
P40121  Macrophage-capping protein   36  579  16  20  Npd 
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Table 2. Cont. 
P02675 
 
Fibrinogen beta chain  37  676  12  26  [23,25] 
38 554  16  36 
39 467  15  20 
P00738  Haptoglobin  40  518  10  21  [28] 
P37837 *Transaldolase 
 
41 60  8  15  [28] 
42 77  6  13 
P25311  Zinc-alpha-2-glycoprotein  43  246  16  28  [22–26] 
44  285  11  20 
P60709  Actin, cytoplasmic 1   45  230  3  15  [23,25] 
46 188  4  15 
P27797  **Calreticulin  47  651  10  27  Npd 
P01024 Complement  C3  48  330  15  6  Npd 
49 332  14  5 
P63261  Actin, cytoplasmic 2  50  285  11  20  [23] 
P60709  Actin, cytoplasmic 1  51  243  5  14  [23,25] 
P52907  F-actin-capping protein subunit 
alpha-1 
52  274  6  16  Npd 
P25311 Zinc-alpha-2-glycoprotein  53  82  3  10  [22–26] 
P12429  Annexin A3  54  331  8  14  Npd 
P00738 Haptoglobin  55  627  12  24  [28] 
P01876  Ig alpha-1 chain C region  56  274  5  17  [22–24,26] 
P30740  *Leukocyte elastase inhibitor  57 417  20  30  [29] 
Q96DR5  *Short palate, lung and nasal 
epithelium carcinoma-associated 
protein 2 
58  141  4  15  [22] 
59  119  5  18 
60  293  20  68 
61       
O00299  *Chloride intracellular channel 
protein 1 
62 561  9  52  Npd 
P63104  Protein kinase C inhibitor 
protein-1(14-3-3 protein 
zeta/delta) 
63  101  4  12  Npd 
P01834  Ig kappa chain C region  64  101  4  33  [23–26] 
P01591  Immunoglobulin J chain  65  241  11  32  [22,24,25] 
P52565 Rho  GDP-dissociation   
inhibitor 1 
66 356  13  30  Npd 
P52566  *Rho GDP-dissociation 
inhibitor 2 
67  173  9  31  Npd 
P09211 Glutathione  S  Transferase  68  201  6  22  [22–24,26] 
69 493  19  61 
P32119  Peroxiredoxin-2  70  264  6  27  [28] 
P02763  Alpha-1-acid glycoprotein 1  71  317  6  27  Npd 
72 137  4  17 
P18510  Interleukin-1 receptor antagonist 
protein 
73  148  6  15  [22,24] 
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Table 2. Cont. 
P00738 
 
Haptoglobin 
 
74 358  6  22  [28] 
75 491  7  20 
76 439  8  22 
P15531  **Nucleoside diphosphate 
kinase A 
77  132  6  25  Npd 
P52566 Rho  GDP-dissociation   
inhibitor 2 
78 185  4  32  Npd 
O15511  Actin-related protein 2/3 
complex subunit 5 
79  69  2  7  Npd 
P12273 
 
Prolactin-inducible protein 
 
80 385  6  45  [22–25] 
81 116  32  6 
82 375  5  44 
83 365  6  45 
84 410  6  45 
85 413  7  54 
86 279  5  45 
P31025 
 
*Lipocalin-1 
 
87  169  5  18  [22,24] 
88  168  3  17 
89  213  4  21 
P01036 *Cystatin  S  90  535  15  62  [22–24,26] 
91 444  8  58 
P09228  *Cystatin SA  92  437  7  64  [22–26] 
P10599 Thioredoxin  93  88  4  16  [21] 
94 111  3  15 
P12273  Prolactin-inducible protein  95  413  7  54  [22–25] 
P02766 Transthyretin  96  80  3  33  [28,33] 
Q14019  **Coactosin-like protein  97  379  8  60  Npd 
P08118 **Beta-microseminoprotein  98  119  2  8  Npd 
P02766  Transthyretin  99  269  7  40  [28,33] 
Q01469 *Fatty  acid-binding  protein, 
epidermal 
100 219  6  47  [22–24,29] 
P01036  *Cystatin S   101  192  4  37  [22–24,26] 
P06702 Calgranulin-B  102  296  6  51  [22,24,26] 
P01040  Cystatin-A   103  42  1  18  [22,25,26] 
P06702 Calgranulin-B  104  395  7  63  [22,24,26] 
P28325  *Cystatin D  105  172  6  34  [22,24] 
Q01469 *Fatty  acid-binding  protein, 
epidermal 
106 347  8  52  [22–24,29] 
Q05315  **Eosinophil lysophospholipase  107  108  3  9  Npd 
P01037 *Cystatin  SN  108  293  20  68  [22–26] 
(a) Accession no. are in accordance to Swiss-Prot; 
(b) Spot numbers are those referred to in Figures 1 
and 2 and identified by MS/MS; Npd—proteins not previously detected in the saliva proteome 
using 2-DE; * Proteins found only in saliva and not in plasma; ** Proteins detected for the first 
time in the saliva proteome of this study. Int. J. Mol. Sci. 2010, 11          
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Among the total of 57 saliva proteins, 35 had been previously identified using 2-DE [32–39], 
whereas 16, including plastin-2, actin-related protein-3, C3 complement precursor, macrophage 
capping protein, F actin capping protein, annexin A3, protein kinase C inhibitor protein-1,   
rho-GDP-dissociation inhibitor 1, rho-GDP-dissociation inhibitor 2, actin-related protein   
2/3 complex subunit 5, alpha-1-acid glycoprotein 1, chloride intracellular channel protein 1,   
protein disulfide-isomerase, leukotriene A-4 hydrolase, IgGFc-binding protein and long palate,   
lung and nasal epithelium carcinoma-associated protein 1, were previously detected using   
liquid-based proteomics [21,23]. The other six saliva proteins, eosinophil lysophospholipase,   
beta-microseminoprotein, coactosin-like protein, nucleoside diphosphate kinase A, calreticulin and 
synaptic vesicle membrane protein VAT-1, are reported for the first time by this study.  
When 2-DE was performed on whole saliva samples of heavy smokers, the profiles obtained were 
similar to those from non-smokers. All 57 different proteins that were expressed in the saliva of the 
non-smokers were also detected in the saliva of the heavy smokers although the rates of presence of  
16 proteins in the 2-DE profiles of the cigarette smokers were different from those of the non-smokers. 
When the 2-DE protein profiles obtained from the non- and heavy smokers were subjected to 
densitometry analysis, initially a significantly enhanced expression of seven proteins including 
polymeric immunoglobulin receptor, complement C3, α1-antitrypsin, calgranulin B, interleukin-1 
receptor antagonist, thioredoxin and lipocalin-1, was detected between the two subject groups. 
However, only three of the proteins, i.e., interleukin-1 receptor antagonist (+3 fold), thioredoxin 
(+2.5 fold) and lipocalin-1 (+4.4 fold) were found to be truly significant when the p-values were 
corrected for false significant results using the method of Benjamini and Hochberg [47] (Table 3). 
Figure 2 demonstrates examples of 2-DE spot clusters of proteins whose levels were altered in the 
saliva obtained from the heavy smokers as compared to those of the non-smokers.  
Table 3.  Densitometry analysis of saliva proteins and their rates of presence in   
2-DE profiles. 
Protein 
Non-smokers Smokers   
% volume
(a) 
(±S.E.M) 
RP
(b)/12 %  volume
(a) 
(±S.E.M) 
RP
(b)/12  p
(c) 
1: Energy/Metabolism           
Amylase  14.15 (±0.54)  12  12.72 (±0.85)  12  0.168 
Carbonic anhydrase VI  1.48 (±0.17)  12  1.07 (±0.14)  12  0.077 
Zinc-alpha-2-glycoprotein  1.02 (±0.09)  12  1.09 (±0.13)  12  0.673 
Fatty acid-binding protein, 
epidermal 
0.08 (±0.01)  12  0.12 (±0.02)  12  0.111 
Transaldolase  0.04 (±0.01)  12  0.04 (±0.01)  12  0.543 
Alpha-enolase  0.06 (±0.02)  10  0.10 (±0.02)  12  0.183 
2: Defence/Immune response          
Polymeric immunoglobulin 
receptor 
4.58 (±0.12)  12  3.57 (±0.40)  12  0.024 
Immunoglobulin J chain  0.38 (±0.06)  12  0.41 (±0.06)  12  0.305 
Interleukin-1 receptor antagonist 
protein 
0.01 (±0.00)  7  0.04 (±0.01)  11  0.004 
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Table 3. Cont. 
Prolactin-inducible protein  2.27 (±0.20)  12  2.35 (±0.23)  12  0.787 
Short palate, lung and nasal 
epithelium carcinoma-associated 
protein 2 
1.22 (±0.18)  11  1.42 (±0.18)  12  0.456 
Alpha-1-acid glycoprotein 1  0.01 (±0.00)  2  0.02 (±0.01)  5  0.159 
3: Protein degradation inhibitor         
α1-Antitrypsin  0.02 (±0.01)  6  0.05 (±0.01)  8  0.027 
Cystatin A  0.08 (±0.02)  12  0.09 (±0.03)  12  0.620 
Cystatin S  0.04 (±0.01)  12  0.05 (±0.01)  12  0.775 
Cystatin SA  0.28 (±0.05)  12  0.27 (±0.07)  12  0.916 
Cystatin SN  0.28 (±0.06)  12  0.30 (±0.04)  12  0.744 
Cystatin D  0.12 (±0.02)  12  0.12 (±0.02)  11  0.769 
Leukocyte elastase inhibitor  0.10 (±0.01)  12  0.10 (±0.01)  12  0.922 
4: Cell adhesion/communication        
Calgranulin B  0.13 (±0.01)  12  0.21 (±0.04)  12  0.032 
5: Protein folding/repair           
Heat shock 70 kDa protein 1  0.06 (±0.01)  12  0.05 (±0.01)  12  0.818 
6: Redox          
Thioredoxin  0.03 (±0.00)  1  0.07 (±0.02)  8  0.001 
Peroxiredoxin-2  0.01 (±0.01)  3  0.02 (±0.01)  7  0.617 
7: Signaling           
Complement C3 precursor  0.00 (±0.00)  3  0.01 (±0.00)  9  0.012 
Glutathione-S Transferase  0.10 (±0.01)  12  0.12 (±0.02)  12  0.444 
Rho GDP-dissociation inhibitor 1  0.14 (±0.03)  3  0.15 (±0.03)  3  0.557 
Rho GDP-dissociation inhibitor 2  0.03 (±0.01)  10  0.04 (±0.01)  12  0.327 
Protein kinase C inhibitor 
protein-1 
0.11 (±0.03)  7  0.17 (±0.05)  11  0.282 
Annexin A3  0.07 (±0.02)  11  0.00 (±0.01)  6  0.088 
8: Structural/cytoskeletal          
F-actin-capping protein subunit 
alpha-1 
0.02 (±0.01)  4  0.03 (±0.01)  8  0.521 
Macrophage-capping protein  0.03 (±0.01)  7  0.02 (±0.00)  9  0.261 
L-plastin  0.11 (±0.01)  12  0.09 (±0.01)  12  0.376 
9: Transport           
Lipocalin-1   0.15 (±0.05)  8  0.65 (±0.13)  12  0.001 
Haptoglobin  0.06 (±0.01)  11  0.07 (±0.01)  12  0.694 
Transthyretin  0.07 (±0.01)  12  0.10 (±0.02)  12  0.108 
Serum albumin  1.63 (±0.14)  12  1.71 (±022)  12  0.758 
(a) volume of a protein expressed as a percentage of the total spot volume of all proteins; 
(b) rate of 
presence of the protein spots in the 12 2-DE profiles that were analyzed; 
(c) p-values of less than 
0.0068 (p  <  0.0068) were considered statistically significant when the false discovery rate 
procedure of Benjamini and Hochberg [47] was performed to the data set.  
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Figure 2. Cropped images of saliva proteins in the 2-DE gels of non-smokers and smokers. 
Representative gels of two differentially expressed saliva proteins are shown. Spot 
numbers are those referred to in Table 2. 
 
 
When the different isoforms of polymeric immunoglobulin receptor (spots 3–9), carbonic anhydrase 
VI (spots 27–32), prolactin inducible proteins (spots 81–86), zinc-alpha-2-glycoprotein (spots 43   
and 44), short palate, lung and nasal epithelium carcinoma-associated protein 1 (spots 58–61) and  
cystatin S (spots 90 and 91) were similarly analyzed by densitometry, their volume distribution 
patterns were found to be consistent between the saliva of non-smokers and smokers. In contrast, the 
2-DE volume distribution pattern for isoforms of lipocalin-1 in the saliva of non-smokers was different 
from that detected in the saliva of the heavy smokers (Figure 3). Among the seven isoforms analyzed, 
the isoform f was almost exclusive to the saliva of the smokers (Table 4). 
Figure 3. Cropped images of lipocalin-1 isoform spots in the 2-DE gels of non-smokers 
and smokers. Six representative gels are shown. The isoform spots a to g are marked in the 
gels (only represented in one of the images so as not to affect image display). Detailed 
densitometry analysis of the isoform spots is demonstrated in Table 4. 
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Table 4. Densitometry analysis of lipocalin-1 isoforms and their rates of presence in 2-DE profiles. 
Isoform 
Spot
(a) 
Non-smokers Smokers 
p 
Fold 
Change
(d)  % vol
(b) RP
(c) %  vol
(b) RP
(c) 
a 0.056  8  0.195  12  0.005  +3.5
b 0.007  4  0.150  10  0.000  +21.4
c 0.085  11  0.305  12  0.012  +3.7
d 0.013  5  0.108  11  0.012  +8.3
e 0.006  4  0.069  9  0.038  +11.5
f 0.003  1  0.089  6  0.031  +29.7
g 0.110  12  0.316  12  0.018  +2.9 
(a) isoforms of lipocalin-1 as depicted in Figure 3; 
(b) volume of a protein expressed as a percentage 
of the total spot volume of all proteins; 
(c) rate of presence of the protein spots in the 12 2-DE 
profiles that were analyzed; 
(d) fold change is the ratio of %vol of smokers to non-smokers. 
4. Discussion 
Human whole saliva contains fluid from the salivary glands, gingival crevicular fluid, bronchiol and 
nasal secretions, desquamated epithelial cells, oral tissues, and very often, the components of blood, 
bacteria and viruses [48–50]. Therefore, whole saliva—in contrast to serum—is a hostile environment 
with proteins subjected to the effects of many host- and bacteria-derived enzymes. Some saliva 
proteins are synthesized in the salivary glands and subsequently subjected to intracellular processing 
including glycosylation, phosphorylation and proteolysis. Once the secretions enter the non-sterile oral 
environment, additional and continuous protein modifications by host- and bacteria-derived enzymes 
occur. This results in the possible generation of many modified proteins in whole saliva [51].  
The 2-DE profiles of proteins in whole saliva from healthy non-smokers that were generated in the 
present study showed strong resemblance to those that were previously reported [22–26]. Almost 90% 
of the protein spots that were highly resolved were eventually identified. The remaining spots were 
unidentifiable as the proteins generated low intensity spectra probably due to their low amounts, 
resistance to proteolytic cleavage, low recovery of digested peptides, and/or low efficiency in peptide 
ionization. Nevertheless, it is also possible that some of the unidentified proteins were of bacterial 
origin since the mouth is likely to harbor a lot of microorganisms.  
In addition to the 35 human saliva proteins that have previously been established by other research 
groups using 2-DE [22–26], the present study detected the presence of 22 additional proteins. This is 
an important contribution to the human saliva proteome as a whole. Among the newly identified 
proteins (see Table 2), nucleotide diphosphate kinase A, annexin A3, Rho-GDP-dissociation inhibitor 1, 
beta-microseminoprotein, chloride intracellular channel protein 1, protein disulfide-isomerase, 
calreticulin, peroxiredoxin-2, alpha-1-acid glycoprotein 1 and IgG Fc-binding protein are considered 
clinically interesting as they have been previously associated with cancer and other diseases [52–61]. 
The establishment of highly resolved 2-DE protein profiles enabled investigations on protein 
changes associated with cigarette smoking. Densitometry analyses on the 2-DE protein profiles 
obtained from the non- and heavy smokers showed differential abundance of interleukin-1 receptor 
antagonist, thioredoxin and lipocalin-1 between the saliva samples of the two subject groups (Table 3). 
The three proteins have good potential to be used as non-specific complementary biomarkers for the Int. J. Mol. Sci. 2010, 11          
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adverse effects of smoking although this requires further evaluation and correlative studies. Some of 
the proteins may be used as risk indicators for inflammatory and chronic diseases that are associated 
with smoking as they have been shown to be of increased levels in the saliva of the patients. In the 
case of lipocalin-1, the isoform distribution pattern detected was also found to differ between smokers 
and non-smokers. This suggests that the carbohydrate moieties of lipocalin-1 of the heavy cigarette 
smokers were different from those of the non-smokers and that they may be differently glycosylated or 
modified. However, this remains to be further established.  
Despite being distinctly categorized according to their primary biological roles [62], the three saliva 
proteins that were altered in abundance reflect the body’s overall response to the damaging effects of 
heavy smoking. The high levels of IL-1 receptor antagonist in the saliva of the heavy smokers detected 
in this study reflect an anti-inflammatory response in the oral cavities of the smokers. Increased 
generation of the proteins in smokers may be induced by the proinflammatory cytokines that were 
promoted by oxidative stress [63–65]. An imbalance between IL-1 receptor antagonist and IL-1 has 
been hypothesized to play a role in the pathogenesis of various inflammatory diseases [65].  
Lipocalin-1 and thioredoxin are proteins most likely involved in the response to stress in relation to 
tissue damage. The high levels of lipocalin-1 and thioredoxin in the cigarette smokers’ saliva may 
reflect their function as an oxidative stress-induced scavenger against toxic and pro-inflammatory 
lipids [66–68]. Lipocalin-1 had been suggested to be a cysteine proteinase inhibitor [67] and may have 
a role in the control of inflammatory processes in oral tissues. Thioredoxin, on the other hand, was 
shown to modulate remodeling factors in response to the cigarette smoke [68]. Increased secretion of 
thioredoxin had been previously demonstrated in the saliva of patients with oral cancer [32].  
5. Conclusion 
Comparative proteomics analysis of human saliva samples from subjects who were considered 
heavy cigarette smokers and those who did not smoke detected altered abundance of interleukin-1 
receptor antagonist, thioredoxin and lipocalin-1, as well as a change in the isoform distribution   
patterns of lipocalin-1. These proteins may be used as early biomarkers to indicate risks of   
tobacco-related diseases.  
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